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LEUKAEMIA’ GENERAL OVERVIEW 
Definition  
• Leukemia (leukaemia) is a group of progressive, 
malignant neoplasms (cancers) of the blood-
forming organs, marked by diffuse replacement 
of the bone marrow development of leukocytes 
and their precursors in the blood and bone 
marrow, accompanied by a reduced number of 
erythrocytes and blood platelets, and resulting 
in anemia, increased susceptibility to infection 
and hemorrhage with weakness and malaise, 
fever, pain in the joints and bones, swelling of the 
lymph nodes, spleen, and liver  
Epidemiology 2 
http://media-2.web.britannica.com/eb-media/15/67715-004-DD03B367.jpg  
Epidemiology 1 
http://media-2.web.britannica.com/eb-media/15/67715-004-DD03B367.jpg  
Risk Factors  
Acute leukemia 
• Chronic exposure to certain 
chemicals (for example 
benzene)   
• Long-term treatment with 
alkylating substances and 
ionizing radiation  
• Mutations in cellular 
oncogenes, tumor 
suppressor genes, and 
transcription factors   
 
Chronic leukemia 
• Sex (men: women is 2:1) and 
genetic factors  (1st degree 
relatives of patients have a more 
than 3 times greater chance to 
develop leukemia) 
• East Asian region   
• Certain retroviruses (some rare 
cases of T-cell leukemia are 
associated with infection of a 
human retrovirus (HTLV I) 
http://oncolex.org/leukemia/background/etiology  
Etiology     
• In almost all cases, the etiology is unknown 
• Different kinds of leukemia are believed to have different 
causes 
• Abnormalities of chromosomes have been found in 
various types of leukemia 
• Whether chromosomal alterations are primary or 
secondary is undetermined, but they are at least 
contributory in the development of leukemia 
• There is an increasing body of evidence incriminating 
viruses in leukemogenesis in man, and they may be a 
factor in all cases 
• Certain chemicals and ionizing radiation  may be 
important etiologic factors in a few cases 
https://en.wikipedia.org/wiki/Leukemia, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1516260/   
Classification 1 
four major kinds of leukemia   
https://en.wikipedia.org/wiki/Leukemia  
Cell type Acute Chronic 
Myelogenous 
leukemia 
("myeloid" or 
"nonlymphocytic") 
Acute myelogenous 
leukemia (AML or 
myeloblastic) 
Chronic 
myelogenous 
leukemia (CML) 
Lymphocytic 
leukemia 
(or "lymphoblastic") 
Acute lymphoblastic 
leukemia (ALL) 
Chronic lymphocytic 
leukemia (CLL) 
Classification 2 
Myeloid Leukemia   
http://medrevise.co.uk/images/thumb/e/e1/All.jpg/450px-All.jpg  
Classification 3 
Lymphoid Leukemia  
http://medrevise.co.uk/images/thumb/e/e1/All.jpg/450px-All.jpg  
MAJOR KINDS OF LEUKEMIA 
(ACUTE MYELOGENOUS & LYMPHOBLASTIC, CHRONIC 
MYELOGENOUS & LYMPHOCYTIC) 
Acute myelogenous leukemia (AML): 
definition 
Acute myelogenous (myeloid, nonlymphocytic) 
leukemia (AML) represents a group of clonal 
hematopoietic stem cell disorders in which both 
a block in differentiation and unchecked 
proliferation result in the accumulation of 
myeloblasts at the expense of normal 
hematopoietic precursors  
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/acute-myelogenous-leukemia/ 
Acute myelogenous leukemia (AML): 
epidemiology 
AML is the most common acute leukemia affecting adults, and 
its incidence increases with age 
http://www.bloodjournal.org/content/bloodjournal/113/18/4179/F1.large.jpg?sso-checked=true  
Acute myelogenous leukemia (AML): 
mechanisms 1 
• AML is characterized by clonal expansion of hematopoietic 
stem and progenitor cells with blocked differentiation 
• AML is the product of several functionally cooperating genetic 
alterations including chromosomal translocations leading to 
expression of leukemogenic fusion proteins 
• Several AML-associated lesions target chromatin regulators 
like histone methyltransferases or histone acetyltransferases, 
including mixed-lineage leukemia 1 (MLL1) or CREB binding 
protein/p300 
• Chromatin modulating mechanisms are mediating the 
transforming activity of key drivers of leukemogenesis by 
aberrant recruitment of corepressors (aberrant DNA, 
aberrantly expressed microRNAs)   
http://www.ncbi.nlm.nih.gov/pubmed/21141731  
Acute myelogenous leukemia (AML): 
mechanisms 2 
AML developing cells  
https://en.wikipedia.org/wiki/Acute_myeloid_leukemia  
Acute myelogenous leukemia (AML): 
classification 
The French-American-British (FAB) classification 
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-classified  
FAB subtype Name 
M0 Undifferentiated acute myeloblastic leukemia 
M1 Acute myeloblastic leukemia with minimal maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia (APL) 
M4 Acute myelomonocytic leukemia 
M4 eos Acute myelomonocytic leukemia with eosinophilia 
M5 Acute monocytic leukemia 
M6 Acute erythroid leukemia 
M7 Acute megakaryoblastic leukemia 
 
 
Acute myelogenous leukemia (AML): 
classification 
• AML with certain genetic abnormalities (translocation 
between chromosomes 8 and 21, translocation or inversion in 
chromosome 16,  translocation between chromosomes 9 and 
11, etc.)  
• AML with myelodysplasia-related changes 
• AML related to previous chemotherapy or radiation 
• AML not otherwise specified (with minimal differentiation 
(M0), without maturation (M1), with maturation (M2), etc.)  
• Myeloid sarcoma (granulocytic sarcoma or chloroma) 
• Myeloid proliferations related to Down syndrome 
• Undifferentiated and biphenotypic acute leukemias   
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-classified  
 
 World Health Organization (WHO) classification 
Acute myelogenous leukemia (AML): 
clinical presentation 1 
Initial clinical presentations are related to pancytopenia, the reduction of 
all cell counts, reflecting the leukemic cell replacement of bone marrow and 
include: 
• Headache/disorientation due to abnormal white blood cells infiltrating the 
central nervous system (CNS) 
• Anemia which is accompanied by pallor, fatigue, malaise, hypoxia, and 
bleeding, caused by rapidly proliferating leukocytes inhibiting formation of 
erythrocytes and thrombocytes 
• Infections (pneumonia) and mouth/throat ulcerations, caused by 
increased numbers of immature or abnormal leukocytes which are unable 
to fight off infections 
• Increased metabolic rate with weakness, pallor, and weight loss, caused by 
increased leukocyte production which require increased nutrient 
production; destruction of cells also increases metabolic waste  
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Characteristics.2FClinical_Presentation  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 2 
• Hyperuricemia which may lead to renal pain, obstruction, and infection 
(later development includes renal insufficiency with uremia), caused by a 
great number of leukocytes being destroyed which releases large amounts 
of uric acid; in late stages, leukocytes infiltrate the kidneys 
• Enlarged organs (spleen, liver), caused by increased number of white 
blood cells accumulating within liver and spleen causing tissue distension 
• Lymphadenopathy and bone pain, caused by excessive number of white 
blood cells accumulating in lymph nodes and bone marrow 
• Bone discomfort (especially in ribs, sternum, and tibia) 
• Older adults may experience delirium, and progressive weakness 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Characteristics.2FClinical_Presentation  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 3 
Paleness of skin 
http://discussingaml.blogspot.com/2015_04_01_archive.html  
 
 
Unexplained bruising Petechiae 
Acute myelogenous leukemia (AML): 
clinical presentation 4 
Severe generalized gingival overgrowth with localized necrosis and sloughing 
involving the interdental papilla 
http://discussingaml.blogspot.com/2015_04_01_archive.html  
 
 
Acute myelogenous leukemia (AML): 
clinical presentation 5 
Signs and symptoms of acute myeloid leukemia 
http://leukemiasymptomsander.blogspot.com/2015/10/signs-and-symptoms-of-acute-myeloid.html  
 
 
Acute myelogenous leukemia (AML): 
diagnosis 1 
• History and Physical Examination: clinical presentation 
• Blood Test: an excess of abnormal white blood cells (leukocytosis), 
sometimes leukemic blasts, isolated decreases in platelets, red blood cells, 
or even with a low white blood cell count (leukopenia) 
• Bone marrow biopsy and aspiration: to diagnose the presence of 
leukemia, to differentiate AML from other types of leukemia (e.g. acute 
lymphoblastic leukemia - ALL), and to identify the subtype of AML 
accordingly to its classifications   
• Immunophenotyping: to determine the subtype of AML by comparing the 
cancer cells to normal cells in the immune system  
https://en.wikipedia.org/wiki/Acute_myeloid_leukemia  
 
 
Acute myelogenous leukemia (AML): 
diagnosis 2 
The following conditions  require differentiation: 
• Acute Lymphoblastic Leukemia (ALL) 
• Agnogenic Myeloid Metaplasia with Myelofibrosis 
• Anemia 
• Aplastic Anemia 
• Bone Marrow Failure 
• Chronic Myelogenous Leukemia 
• Lymphoma, B-cell 
• Lymphoma, Lymphoblastic 
• Myelodysplastic Syndrome 
• Agranulocytosis (severe subset of neutropenia) 
• Myelophthisic Anemia 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute myelogenous leukemia (AML): 
diagnosis 3 
Malignant myeloid cells  
http://imagebank.hematology.org/AssetDetail.aspx?AssetID=3356 https://www.oumedicine.com/pathology/education/web-based-learning/case-reports/case-1  
http://pathology.jhu.edu/cytopath_tut/Considerations/ShowImage.cfm?ModuleID=3&CaseInfoID=27&ImageID=531&ConsiderID=156  
 
 
Acute myelogenous leukemia (AML): 
diagnosis  
Immunophenotyping 
http://wiki.clinicalflow.com/Cases/Case_List/Acute_Myelogenous_Leukemia_(AML)_not_otherwise_categorized_-_General_Information/AMML_(Acute_Myelomonocytic_Leukemia)_(M4)  
 
 
Acute myelogenous leukemia (AML): 
treatment 1 
The primary treatment is chemotherapy, which can be divided into three 
phases: 
• The first  (Induction) phase clears the blood of leukemia cells and reduces 
the number of blasts in the bone marrow with the goal to return blood 
counts to a normal level over time and to reach a complete remission 
• The second (Consolidation) phase is administered after a rest period 
where the patient recovers from the first phase with the goal to kill the 
small number of leukemia cells that are still present  
• The third (Maintenance) phase is necessary in only certain types of 
leukemia and includes giving low doses of a chemo drug for months or 
years after the consolidation phase  
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute myelogenous leukemia (AML): 
treatment 2a 
There are 4 types of standard treatments: 
1) Chemotherapy: systemic,  intrathecal, or regional drugs  usage depends 
of the AML subtype to stop the growth either to kill cancer cells or to 
stop their dividing  
2) Radiation: different types of radiation to kill cancer cells or keep them 
from growing through  external and internal (radioactive material 
encapsulated in needles, seeds, wires, or catheters placed directly into 
the affected region) approaches which depend of the AML subtype 
3) Stem Cell Transplant: method of administering chemo and replacing 
blood forming cells that are affected or destroyed by the cancer 
treatment  
4) Targeted Therapy: monoclonal antibodies or other substances to destroy 
specific cancer cells without harming the patient's normal cells 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute myelogenous leukemia (AML): 
treatment 2b 
Chemotherapy in the first  (Induction) phase: 
• All FAB subtypes except M3 are usually given with cytarabine (ara-C) and 
an anthracycline (most often daunorubicin)  in different regimens (3+7, 
etc.) 
• The M3 subtype is almost universally treated with the drug all-trans-
retinoic acid (ATRA) in addition to induction chemotherapy, usually an 
anthracycline   
• Because of the toxic effects of therapy, including myelosuppression and an 
increased risk of infection, induction chemotherapy may not be offered to 
the very elderly, and the options may include less intense chemotherapy 
or palliative care   
https://en.wikipedia.org/wiki/Acute_myeloid_leukemia  
 
 
Acute myelogenous leukemia (AML): 
treatment 2c 
Chemotherapy in the second (Consolidation) phase: 
• Even after complete remission is achieved, leukemic cells likely remain in 
numbers too small to be detected with current diagnostic techniques, and 
more therapy is necessary to prevent relapse  
• The specific type of consolidation therapy is individualized based on a 
patient's prognostic factors and general health   
• For patients who are not eligible for a stem cell transplant, 
immunotherapy with a combination of histamine dihydrochloride 
(Ceplene) and interleukin 2 (Proleukin) after the completion of 
consolidation has been shown to reduce the absolute relapse risk by 14%, 
translating to a 50% increase in the likelihood of maintained remission  
  
https://en.wikipedia.org/wiki/Acute_myeloid_leukemia  
 
 
Acute myelogenous leukemia (AML): 
treatment 2d 
• When receiving chemotherapy, patients should avoid exposure to crowds 
and people with contagious illnesses, especially children with viral 
infections. Any patient with neutropenic fever or infection should 
immediately be treated with broad-spectrum antibiotics 
• Appropriate transfusion support includes transfusion of platelets and 
clotting factors (fresh frozen plasma - FFP, cryoprecipitate) as guided by 
the patient’s blood test results and bleeding history 
• For Patients with relapsed AML the only proven potentially curative 
therapy is a hematopoietic stem cell transplant, if one has not already 
been performed  
https://en.wikipedia.org/wiki/Acute_myeloid_leukemia  
 
 
Acute myelogenous leukemia (AML): 
treatment 3 
Physical Therapy and exercise  are aimed at symptom management, 
preservation of muscle function, pain control, and increased quality of life 
and include: 
• Up to 15 minutes of walking 5x per week can reduce fatigue, symptom 
distress, anxiety, and depressive status while maintaining cardiovascular 
health 
• Strength training  combined with aerobic exercises 3x per week, twice 
daily, for 30 minutes improves cardiorespiratory endurance, reduces total 
fatigue and depression, maintains quality of life, and may reduce 
inflammatory markers 
• Pain management (transcutaneous electrical nerve stimulation (TENS), hot 
packs, cold packs, massage, etc. ) 
• Stretching (sustained stretch, active and passive range of motion (ROM), 
splinting, etc.) 
 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute myelogenous leukemia (AML): 
treatment 4 
• Patients should be instructed to call their healthcare providers 
immediately if they are febrile or have signs of bleeding  
• Patients are best treated at a center whose staff has significant experience 
in the treatment of leukemia 
• Patients should be transferred to an appropriate (generally tertiary care) 
hospital if they are admitted to hospitals without appropriate blood 
product support, leukapheresis capabilities, or physicians and nurses 
familiar with the treatment of leukemia patients  
 
http://emedicine.medscape.com/article/197802-treatment  
 
 
Acute myelogenous leukemia (AML): 
prognosis 
• Acute myeloid leukemia is a curable disease, and the chance of cure for a 
specific patient depends on a number of prognostic factors 
• Increasing age is an adverse factor, because older patients more 
frequently have a previous antecedent hematologic disorder along with 
comorbid medical conditions that compromise the ability to give full doses 
of chemotherapy 
• A previous antecedent hematologic disorder is associated with a poor 
outcome to therapy 
http://emedicine.medscape.com/article/197802-overview#a6  
 
 
Acute myelogenous leukemia (AML): 
clinical case 1 
• . 
• The case of a 14-year-old female with acute myeloid leukemia (AML) and 
myeloid sarcomas (MS) in the anterior mediastinum and around 
numerous bones 
• Laboratory tests showed a white blood cell count of 4.0 × 10(9)/l with 
7.0 % blasts 
• Computed tomography revealed a mediastinal mass and pleural effusion; 
pleural effusion cytology was negative for malignant cells 
• In addition, disseminated intravascular coagulation (DIC) was present 
Following DIC therapy, thoracoscopic and bone marrow biopsies were 
performed  
http://dgcases.docguide.com/acute-myeloid-leukemia-mediastinal-myeloid-sarcoma-refractory-acute-myeloid-leukemia-therapy  
 
 Acute myeloid leukemia with mediastinal myeloid sarcoma 
refractory to acute myeloid leukemia therapy but responsive to 
L-asparaginase 
Acute myelogenous leukemia (AML): 
clinical case 2 
• Immunostaining and surface marker analysis revealed that the blast cells 
were positive for cytoplasmic myeloperoxidase, CD4, CD7, CD33, CD44, 
CD117, and HLA-DR, but negative for CD34 and CD56 
• Karyotype was normal 
• MS associated with AML was diagnosed 
• Multidrug chemotherapy for AML was completely ineffective, and MS 
continued to progress 
• Immunohistochemistry revealed that the blasts were negative for 
asparagine synthetase (AS); therefore, chemotherapy including L: -
asparaginase was initiated  
http://dgcases.docguide.com/acute-myeloid-leukemia-mediastinal-myeloid-sarcoma-refractory-acute-myeloid-leukemia-therapy  
 
 Acute myeloid leukemia with mediastinal myeloid sarcoma 
refractory to acute myeloid leukemia therapy but responsive 
to L-asparaginase 
Acute myelogenous leukemia (AML): 
clinical case 3 
• After the first administration of L: -asparaginase, the patient's condition 
improved; however, she subsequently developed tumor lysis syndrome 
and sepsis, which eventually led to death 
• Aggressive MS in childhood is rare and refractory to existing AML 
chemotherapy 
• Chemotherapy including L -asparaginase may prove to be effective in such 
cases, especially those in which blast cells show negative AS expression 
 
From: Department of Hematology/Oncology, Saitama Children's Medical 
Center, 2100 Magome, Iwatsuki-ku, Saitama, Japan 
http://dgcases.docguide.com/acute-myeloid-leukemia-mediastinal-myeloid-sarcoma-refractory-acute-myeloid-leukemia-therapy  
 
 Acute myeloid leukemia with mediastinal myeloid sarcoma 
refractory to acute myeloid leukemia therapy but responsive 
to L-asparaginase 
Acute lymphoblastic leukemia (ALL): 
definition 
Acute lymphoblastic (lymphocytic, lymphoid) 
leukemia (ALL) represents a group of clonal 
hematopoietic stem cell disorders in which both 
a block in differentiation and unchecked 
proliferation result in the accumulation 
of  lymphoblasts at the expense of normal 
hematopoietic precursors  
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia  
Acute lymphoblastic  leukemia (ALL): 
epidemiology 
Incidence of acute lymphoblastic leukemia (ALL) by age 
http://asheducationbook.hematologylibrary.org/content/2006/1/128/F1.expansion  
Acute lymphoblastic  leukemia (ALL): 
mechanisms 1 
• ALL is caused by damage to DNA that leads to uncontrolled 
cellular growth and spreads throughout the body, either by 
increasing chemical signals that cause growth or by 
interrupting chemical signals that control growth 
• Damage can be caused through the formation of fusion genes, 
as well as the dysregulation of a proto-oncogene via 
juxtaposition of it to the promoter of another gene, e.g. the T-
cell receptor gene by environmental factors such as chemicals, 
drugs or radiation, and occurs naturally during mitosis or 
other normal processes 
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia#Pathophysiology  
Acute lymphoblastic  leukemia (ALL): 
mechanisms 2 
ALL develops’ cells  
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia#Pathophysiology  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
• Two subtypes of ALL: 
• B-cells produce antibodies to fight infections 
• Common ALL (50% of cases) 
• Early Pre-B ALL (10% of cases) 
• Pre-B ALL (10% of cases) 
• Mature B-cell ALL (4% of cases)  
• T-cells assist B-cells in producing antibodies to 
fight infections 
• Pre-T ALL (5-10% of cases) 
• Mature T-cell (15-20% of cases)  
Acute lymphoblastic  leukemia (ALL): 
classification 
The French-American-British (FAB) classification 
http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-classified  
 
 
Division of ALL according to FAB criteria 
L1 – cytoplasma-deficient, small blasts 
L2 – more heterogenous with emphasis on cytoplasma 
richness and size 
L3 – B-cell blasts with basophile vacuolized cytoplasma  
Acute lymphoblastic  leukemia (ALL): 
classification 
http://imaging.ubmmedica.com/cancernetwork/cmhb13/13_29_Table2.gif  
 
 World Health Organization (WHO) classification 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 1 
Most signs and symptoms mimic those of the flu and include: 
• Anemia 
• Dizziness 
• Weakness 
• Fatigue 
• Shortness of breath 
• Frequent or unexplained fever and infection 
• Weight loss and/or loss of appetite 
• Bleeding from the gums and/or nose 
• Pale skin 
• Excessive and unexplained bruising due to low platelet levels 
• Swollen lymph nodes (neck, underarm, groin, stomach) 
• Bone pain, joint pain (the spread of "blast" cells from the marrow cavity) 
• Pitting edema (swelling) in the lower limbs and/or abdomen  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 3 
Paleness of skin 
http://www.texaschildrensblog.org/2013/01/my-2-year-old-son-survived-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia/  
http://leukemiasymptomsander.blogspot.com/2015/02/leukemia-symptoms-petechiae.html  
 
 
Unexplained bruising Petechiae 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 4 
Severe generalized gingival overgrowth with localized necrosis and sloughing 
involving the interdental papilla 
http://discussingaml.blogspot.com/2015_04_01_archive.html  
 
 
Acute lymphoblastic  leukemia (ALL): 
clinical presentation 5 
Signs and symptoms of acute lymphoblastic leukemia 
http://leukemiasymptomsander.blogspot.com/2015/10/signs-and-symptoms-of-acute-myeloid.html  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis 1 
• History and Physical Examination: clinical presentation 
• Blood Test: an excess of abnormal white blood cells (leukocytosis), 
sometimes leukemic blasts, isolated decreases in platelets, red blood cells, 
or even with a low white blood cell count (leukopenia) 
• Bone marrow biopsy and aspiration: to diagnose the presence of leukemia, 
to differentiate ALL from other types of leukemia, and to identify the 
subtype of ALL accordingly to its classifications   
• Immunophenotyping: to determine the subtype of ALL by comparing the 
cancer cells to normal cells in the immune system (may reveal terminal 
deoxynucleotidyl transferase (TdT -a specialized DNA polymerase expressed 
in immature, pre-B, pre-T lymphoid cells, and ALL/lymphoma cells or 
common acute lymphoblastic leukemia antigen (CALLA)   
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia#Pathophysiology  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis 2 
The following conditions  require differentiation: 
• Acute Lymphoblastic Leukemia (ALL) 
• Agnogenic Myeloid Metaplasia with Myelofibrosis 
• Anemia 
• Aplastic Anemia 
• Bone Marrow Failure 
• Chronic Myelogenous Leukemia 
• Lymphoma, B-cell 
• Lymphoma, Lymphoblastic 
• Myelodysplastic Syndrome 
• Agranulocytosis (severe subset of neutropenia) 
• Myelophthisic Anemia 
http://www.physio-pedia.com/Acute_Myeloid_Leukemia#Diagnostic_Tests.2FLab_Tests.2FLab_Values  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis 3 
Malignant lymphoblastic cells  
https://en.wikipedia.org/wiki/B-cell_lymphoma https://www.pinterest.com/pin/287526757435867609/ http://www.donationto.com/blog/fundraising-for-acute-lymphoblastic-leukemia-all/ 
  
 
 
Acute lymphoblastic  leukemia (ALL): 
diagnosis  
Example of immunophenotyping plots: A: Simply classification of T Cells [in blue] 
(CD3+) and B Cells [in purple] (CD19+) (i); with lymphocytes [in blue and purple] 
distinguished by Forward and Side Scatter (ii). B: Classification of eosinophils [in 
red] as SiglecF+ (i) F4/80intCD11bint (ii) Ly6G-/lowCD11c– (iii) FSCloSSCint/hiSiglecF+ (iv). 
  
http://bitesizebio.com/22238/immunophenotyping-identifying-whos-who-in-the-cellular-world/  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 1 
Treatment can span 2 ½ - 3 ½ years depending on each individual situation 
and is broken down into the following 4 phases: 
1. Induction therapy with the purpose to achieve remission by killing most 
of the cancer cells in the blood and bone marrow (chemotherapy drugs 
injected intrathecally, steroids, the anthracyclines)  
2. Consolidation (post-remission) therapy with the goal to destroy any 
remaining leukemia cells in the central nervous system (4 - 8 weeks)   
3. Maintenance (low dose) therapy is given to prevent cancer cell re-growth 
(4 weeks) 
4. Preventive therapy to the spinal cord (chemotherapy drugs are injected 
directly into the spinal cord fluid)  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 2 
There are 4 main types of the specific treatments : 
• Chemotherapy (all patients need spinal taps to inject chemotherapy into 
the cerebrospinal fluid (CSF) to kill any leukemia cells that may have 
spread to the brain and spinal cord)  
• Targeted drug therapy to attack specific abnormalities that cause the 
cancer cell growth 
• Radiation therapy is typically used when the cancer has spread to the 
central nervous system 
• Stem cell transplant (SCT) may be used for patients at risk or currently 
going through a relapse  
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 3 
Physical Therapy and exercise  are aimed at symptom management, 
preservation of muscle function, pain control, and increased quality of life 
and include: 
• Up to 15 minutes of walking 5x per week can reduce fatigue, symptom 
distress, anxiety, and depressive status while maintaining cardiovascular 
health 
• Strength training  combined with aerobic exercises 3x per week, twice 
daily, for 30 minutes improves cardiorespiratory endurance, reduces total 
fatigue and depression, maintains quality of life, and may reduce 
inflammatory markers 
• Pain management (transcutaneous electrical nerve stimulation (TENS), hot 
packs, cold packs, massage, etc.  
• Stretching (sustained stretch, active and passive range of motion (ROM), 
splinting, etc.) 
 
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
 
 
Acute lymphoblastic  leukemia (ALL): 
treatment 4 
Medications: 
• Chemotherapy drugs: L - asparaginase, Vincristine 
• Steroid: Dexamethasone, Hydrocortisone 
• Drugs for high-risk patients: Daunorubicin, Cytarabine 
• Other drugs that may be given early: Methotrexate, 6-mercaptopurine  
Novel approaches: 
• For some subtypes of relapsed ALL, aiming at biological targets such as the 
proteasome, in combination with chemotherapy, has given promising 
results in clinical trials 
• Chimeric antigen receptors (CARs) have been developed as a promising 
therapy for ALL 
http://www.physio-pedia.com/Acute_Lymphoblastic_Leukemia#Definition.2FDescription.5B1.5D.5B2.5D.5B3.5D.5B4.5D  
https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia#Diagnosis  
 
 
Acute lymphoblastic  leukemia (ALL): 
prognosis 
• Acute lymphoblastic leukemia is a curable disease, and the chance of cure 
for a specific patient depends on a number of prognostic factors (females 
tend to fare better than males; Caucasians are more likely to develop 
acute leukemia than African-Americans, Asians, or Hispanics; children 1–
10 years of age are most likely to develop ALL and to be cured of it; cases 
in older patients are more likely to result from chromosomal 
abnormalities, etc.)   
• The 5-year survival rate has improved from zero six decades ago, to 85% 
currently, largely because of clinical trials on new chemotherapeutic 
agents and improvements in SCT technology 
http://emedicine.medscape.com/article/197802-overview#a6  
 
 
Acute lymphoblastic  leukemia (ALL): 
clinical case 1   
• Donor cell leukemia (DCL) is a rare but severe complication after allogeneic 
stem cell transplantation 
• The mechanisms of leukemogenesis are unclear, and multiple factors can 
contribute to the development of DCL 
• In recent years, cord blood has emerged as an alternative source of 
hematopoietic progenitor cells, and at least 12 cases of DCL have been 
reported after unrelated cord blood transplantation 
• A new case of DCL after unrelated cord blood transplantation in a 44-year-
old woman diagnosed as having ALL with t(1;19) that developed AML with 
normal karyotype and nucleophosmin (NPM1) mutation in donor cells 
• This is the first report of NPM1 mutation contributing to DCL development 
http://dgcases.docguide.com/mutation-npm1-gene-contributes-development-donor-cell-derived-acute-myeloid-leukemia-after-unrelated  
 
 Donor cell leukemia (DCL) 
Acute lymphoblastic  leukemia (ALL): 
clinical case 2a  
• Therapy-related ALL develops in patients after chemotherapy and/or 
radiotherapy for a prior cancer, and most cases are AML with a much lower 
frequency of ALL 
• One unique feature of these therapy-related ALL (t-ALL) is an increased 
incidence of chromosome band 11q23 aberrations as compared with de 
novo ALL 
• There was a report about the case of a 49-year-old Taiwanese lady who 
developed t-ALL with t(4;11)(q21;q23) 16 months after cyclophosphamide, 
epirubicin, and 5-fluorouracil chemotherapy for her breast cancer 
• The unusual feature is that the t-ALL was heralded 4 months ago by 
marrow lymphocytosis comprising atypical small lymphocytes with 
condensed chromatin mimicking a B-cell chronic lymphoproliferative 
disorder  
http://dgcases.docguide.com/therapy-related-acute-lymphoblastic-leukemia-t411q21q23-masqueraded-marrow-lymphocytosis-patient  
 
 Therapy-related ALL 
Acute lymphoblastic  leukemia (ALL): 
clinical case 2b  
• Retrospective studies using additional antibodies for immunophenotyping 
and PCR-based clonality study for immunoglobulin gene rearrangement 
showed that these atypical small lymphocytes shared similar features with 
the leukemic blasts at the frank leukemic stage 
• The results suggest that these atypical small lymphocytes are lymphoblasts 
in disguise and that the clinicopathological correlations with ancillary 
pathological studies are important to reach a definitive diagnosis of such 
an unusual case 
http://dgcases.docguide.com/therapy-related-acute-lymphoblastic-leukemia-t411q21q23-masqueraded-marrow-lymphocytosis-patient  
 
 Therapy-related ALL 
Chronic myelogenous leukemia (CML): 
definition 
Chronic myelogenous (myeloid, myelocytic, 
granulocytic) leukemia (CML) is the clonal 
hematopoietic stem cell disorder with an 
abnormal increase in mature and immature 
granulocytes (as neutrophils, eosinophils, and 
myelocytes) especially in bone marrow and 
blood, that occurs especially in adults, and that 
is associated with the presence of the 
Philadelphia chromosome CML   
http://www.merriam-webster.com/medical/chronic%20myelogenous%20leukemia  
Chronic myelogenous leukemia (CML): 
epidemiology 
Incidence of CML by age 
http://seer.cancer.gov/statfacts/html/cmyl.html  
Chronic myelogenous leukemia (CML): 
mechanisms 1 
• CML is a biphasic disease, initiated by the 'Philadelphia 
chromosome‘ expression of the BCR - ABLfusion gene product 
in self-renewing, haematopoietic stem cells (HSCs) 
• HSCs can differentiate into common myeloid progenitors 
(CMPs), which then differentiate into granulocyte / 
macrophage progenitors (GMPs; progenitors of granulocytes 
(G) and macrophages (M)) and megakaryocyte / erythrocyte 
progenitors (MEPs; progenitors of red blood cells (RBCs) and 
megakaryocytes (MEGs), which produce platelets) 
• HSCs can also differentiate into common lymphoid 
progenitors (CLPs), which are the progenitors of lymphocytes 
such as T cells and B cells 
http://www.medscape.com/viewarticle/500691  
Chronic myelogenous leukemia (CML): 
mechanisms 2 
• The initial chronic phase (3-4 years) of CML (CML-CP) is 
characterized by a massive expansion of the granulocytic-cell 
series 
• Acquisition of additional genetic mutations beyond expression 
of BCR-ABL causes the progression of CML from chronic phase 
to blast phase (CML-BP) by a block of cell differentiation that 
results in the presence of 30% or more myeloid or lymphoid 
blast cells in peripheral blood or bone marrow, or the 
presence of EXTRAMEDULLARY infiltrates of blast cells, 
characterized by an accumulation of myeloid (2/3 patients) or 
lymphoid blast cells (1/3 patients) 
• Although the CML stem cell is multipotent, production of B 
cells from the neoplastic clone occurs only at low levels, and 
only rare T-cell precursors can be detected  
http://www.medscape.com/viewarticle/500691  
Chronic myelogenous leukemia (CML): 
mechanisms 3 
Philadelphia chromosome 
http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=44179  
Chronic myelogenous leukemia (CML): 
mechanisms 4 
The development of CML 
http://www.medscape.com/viewarticle/500691  
Chronic myelogenous leukemia (CML): 
classification 1 
• Chronic phase: there are few blast cells in the blood and bone 
marrow and there may be no symptoms of leukemia, this 
phase may last from several months to several years  
• Accelerated phase: there are more blast cells in the blood and 
bone marrow, and fewer normal cells  
• Blastic phase (the blast crisis): more than 30% of the cells in 
the blood or bone marrow are blast cells and the blast cells 
may form tumors outside of the bone marrow in places such 
as the bone or lymph nodes 
• Refractory CML: leukemia cells do not decrease even though 
treatment is given  
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
 
 
Chronic myelogenous leukemia (CML): 
classification 2 
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
Chronic phase 
Untreated      Treated 
< 15 % blast cells in blood or 
bone marrow 
< 30 % – the sum of blast cells 
and promyelocytes in blood or 
bone marrow 
< 20 % basophile granulocytes 
in peripheral blood 
Thrombocyte count > 100 x 
109/l 
Normal or close to normal 
blood values 
without immature 
granulocytes in the  blood 
Chronic myelogenous leukemia (CML): 
classification 3 
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
Accelerated phase 
Blast count between 15–29 % in blood or bone marrow 
≥ 30 %, the sum of blast cells and promyelocytes in blood or 
blood marrow 
≥ 20 % basophile granulocytes in blood 
Thrombocyte count < 100 x 109/l, which cannot be explained by 
treatment   
Often also increasing splenomegaly  
new chromosome changes in Ph+ clone 
Chronic myelogenous leukemia (CML): 
classification 4 
http://www.medicinenet.com/script/main/art.asp?articlekey=15477  
Blast phase 
Characterized by >30 % of the cells in blood or bone marrow 
are blasts  
Patients have symptoms of acute leukemia  
Extramedullary illness  
Chronic myelogenous leukemia (CML): 
clinical presentation 1 
The way CML presents depends on the stage of the disease:   
• Most patients (~90%) are diagnosed during the chronic stage which is most 
often asymptomatic, and may be diagnosed incidentally with an 
elevated white blood cell count on a routine laboratory test 
• It can also present with symptoms indicative of enlarged spleen and liver and 
the resulting upper quadrant pain this causes 
• The enlarged spleen may put pressure on the stomach causing a loss of 
appetite and resulting weight loss 
• It may also present with mild fever and night sweats due to an elevated basal 
level of metabolism 
• Some (<10%) are diagnosed during the accelerated stage which most often 
presents bleeding, petechiae and ecchymosis, when  fevers are most 
commonly the result of opportunistic infections 
• Some patients are initially diagnosed in the blast phase in which the symptoms 
are most likely fever, bone pain and an increase in bone marrow fibrosis 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
clinical presentation 3 
Splenomegaly in CML 
http://hubpages.com/health/Clinical-Manifestations-Diagnosis-And-The-Treatment-Plan-Of-Chronic-Myeloid-Leukemia-CML  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis 1 
• CML is often suspected on the basis of a complete blood count, which 
shows increased granulocytes of all types, typically including 
mature myeloid cells 
• Basophils and eosinophils are almost universally increased; this feature may 
help differentiate CML from a leukemoid reaction 
• A bone marrow biopsy is often performed as part of the evaluation for CML, 
and CML is diagnosed by cytogenetics that detects the translocation 
t(9;22)(q34;q11.2) which involves the ABL1 gene in chromosome 9 and the 
BCR gene in chromosome 22: as a result of this translocation, the 
chromosome looks smaller than its homologue chromosome, and this 
appearance is known as the Philadelphia chromosome chromosomal 
abnormality   
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis 2 
• Thus, CML can be detected by routine cytogenetics, and the involved genes 
BCR-ABL1 can be detected by fluorescent in situ hybridization, as well as 
by polymeric chain reaction (PCR)  
• Controversy exists over so-called Ph-negative CML, or cases of suspected 
CML in which the Philadelphia chromosome cannot be detected: many such 
patients in fact have complex chromosomal abnormalities that mask the 
(9;22) translocation, or have evidence of the translocation in spite of 
normal routine karyotyping 
• The small subset of patients without detectable molecular evidence of bcr-
abl fusion may be better classified as having an undifferentiated 
myelodysplastic/myeloproliferative disorder, as their clinical course tends to 
be different from patients with CML  
• CML must be distinguished from a leukemoid reaction, which can have a 
similar appearance on a blood smear 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Classification  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis 3 
A small, hypolobated megakaryocyte (center of field) in a bone marrow aspirate, 
typically of CML 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia  
 
 
Chronic myelogenous leukemia (CML): 
diagnosis  
This chronic myelomonocytic leukemia-
2 was morphologically composed of (A, 
Wright, ×400) 14% immature monocytic 
cells (blasts and promonocytes) and 
26% mature monocytes. The flow 
cytometric immunophenotypic data 
revealed 54% of cells within the 
"monocytic" region (B; orange), which 
revealed uniform bright expression of 
CD11b (C), CD14 (D), and CD33 (E) with 
moderate expression of CD64 (F), partial 
loss of expression of CD15 (C), complete 
loss of expression of CD13 (D), and 
aberrant dim expression of CD2 (G). 
FITC, fluorescein isothiocyanate; PE, 
phycoerythrin 
http://www.medscape.com/viewarticle/495047_3  
 
 
Chronic myelogenous leukemia (CML): 
treatment 1 
• The only curative treatment for CML is a bone marrow transplant or an 
allogeneic stem cell transplant 
• Other than this there are four major mainstays of treatment in CML: 
• treatment with tyrosine kinase inhibitors 
• myelosuppressive or leukopheresis therapy (to counteract 
the leucocytosis during early treatment) 
• splenectomy and interferon alfa-2b treatment  
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 2 
Chronic phase 
• In the past, antimetabolites (e.g., cytarabine, hydroxyurea), alkylating 
agents, interferon alfa 2b, and steroids were used as treatments of CML in the 
chronic phase, but since the 2000s have been replaced by Bcr-Abl tyrosine-
kinase inhibitor drugs that specifically target BCR-ABL, the constitutively 
activated tyrosine kinase fusion protein caused by the Philadelphia 
chromosome translocation 
• Despite the move to replacing cytotoxic antineoplastics (standard anticancer 
drugs) with tyrosine kinase inhibitors sometimes hydroxyurea is still used to 
counteract the high WBCs encountered during treatment with tyrosine kinase 
inhibitors like imatinib; in these situations it may be the preferred 
myelosuppressive agent due to its relative lack of leukemogenic effects and 
hence the relative lack of potential for secondary haematologic malignancies 
to result from treatment 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 3 
Imatinib 
• The first of this new class of drugs was imatinib mesylate, approved by the 
U.S. Food and Drug Administration (FDA) in 2001 
• Imatinib was found to inhibit the progression of CML in the majority of 
patients (65–75%) sufficiently to achieve regrowth of their normal bone 
marrow stem cell population (a cytogenetic response) with stable proportions 
of maturing white blood cells 
• Since the advent of imatinib, CML has become the first cancer in which a 
standard medical treatment may give to the patient a normal life expectancy 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 4 
Dasatinib, nilotinib and radotinib 
• To overcome imatinib resistance and to increase responsiveness to TK 
inhibitors, three novel agents were later developed 
• Dasatinib, blocks several further oncogenic proteins, in addition to more 
potent inhibition of the BCR-ABL protein, and was initially approved in 2007 
by the US FDA to treat CML in patients who were either resistant to or 
intolerant of imatinib 
• Nilotinib, was also approved by the FDA for the same indication in 2010 
• Radotinib joined the class of novel agents in the inhibition of the BCR-ABL 
protein and was approved in South Korea in 2012 for patients resistant to or 
intolerant of imatinib 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 5 
Treatment-resistant CML 
• While capable of producing significantly improved responses compared with 
the action of imatinib, neither dasatinib nor nilotinib could overcome drug 
resistance caused by one particular mutation found to occur in the structure 
of BCR-ABL known as the T315I mutation 
• Two approaches were developed to the treatment of CML as a result: 
• In September 2012, the FDA approved a non BCR-ABL targeted 
agent omacetaxine, administered subcutaneously (under the skin) in 
patients who had failed with imatinib and exhibited T315I kinase domain 
mutation 
• In December 2012 , the FDA approved a new pan-BCR-ABL inhibitor 
Ponatinib which showed (for the first time) efficacy against T315I, as well 
as all other known mutations of the oncoprotein    
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
treatment 5 
Vaccination 
 
In 2005, encouraging but mixed results of vaccination were reported with 
the BCR/abl p210 fusion protein in patients with stable disease, with GM-CSF as 
an adjuvant  
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Treatment  
 
 
Chronic myelogenous leukemia (CML): 
prognosis 
• Before the advent of tyrosine kinase inhibitors, the median survival time 
for CML patients had been about 3–5 years from time of diagnosis 
• With the use of tyrosine kinase inhibitors, survival rates have improved 
dramatically 
• A 2006 follow up of 553 patients using imatinib found an overall survival 
rate of 89% after five years  
• A 2011 follow up of 832 patients using imatinib who achieved a stable 
cytogenetic response found an overall survival rate of 95.2% after 8 years, 
which is similar to the rate in the general population. Less than 1% of 
patients died because of leukemia progression 
https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Prognosis  
 
 
Chronic myelogenous leukemia (CML): 
clinical case 1a   
• Initial identification of CML is very important since targeted therapy leads 
to life-saving remission 
• Doctors describe a case of chronic myelogenous leukemia in blast crisis in a 
previously healthy 61-year-old woman 
• The patient presented with fever, myalgias, and night sweats and was first 
worked up for an infectious etiology 
• Because of persistent anemia, a bone marrow biopsy was performed that 
revealed fibrosis with increased megakaryoblasts  
http://dgcases.docguide.com/unusual-case-philadelphia-chromosome-positive-chronic-myelogenous-leukemia-trisomy-19-presenting  
 
 An unusual case of Philadelphia chromosome-positive CML 
with trisomy 19 presenting with megakaryoblastosis and 
myelofibrosis 
Chronic myelogenous leukemia (CML): 
clinical case 1b   
• Even though initial cytogenetic studies could not be performed because of 
'dry tap' aspirate, persistent efforts for cytogenetic studies were made, 
including a 'squeeze preparation' from the core biopsy, which revealed 
t(9;22)(q34;q11.2) and trisomy 19 
• The patient was treated with tyrosine kinase inhibitors, chemotherapy, and 
subsequently an allogeneic stem cell transplant 
• She is in persistent remission 
• This case illustrates a complex presentation of chronic myelogenous 
leukemia and provides an overview of morphologic cues and the 
importance of performing cytogenetic studies that led to the diagnosis 
http://dgcases.docguide.com/unusual-case-philadelphia-chromosome-positive-chronic-myelogenous-leukemia-trisomy-19-presenting  
 
 An unusual case of Philadelphia chromosome-positive CML 
with trisomy 19 presenting with megakaryoblastosis and 
myelofibrosis 
Chronic myelogenous leukemia (CML): 
clinical case 2   
• Chronic myelogenous leukemia (CML) is very rare in the pediatric 
population 
• Doctors report the case of a 2-year-old female with CML and concurrent 
myelodysplastic syndrome (MDS) associated cytogenetic abnormalities 
• The co-existence of t(9;22) and chromosomal deletions that are associated 
with MDS poses a unique diagnostic challenge 
• Given the reported association of t(9;22) and genomic instability, doctors 
hypothesize that the chromosomal deletions represent clonal evolution of 
the CML 
http://dgcases.docguide.com/myelodysplastic-syndrome-mds-associated-cytogenetic-abnormalities-pediatric-chronic-myelogenous  
 
 Myelodysplastic syndrome (MDS)-associated cytogenetic 
abnormalities in pediatric CML 
Chronic myelogenous leukemia (CML): 
clinical case 3a   
• A 68-year-old man complained of dizziness and was referred to hospital by 
his primary physician for evaluation of an elevated leukocyte count 
• In April 2002, soon after the chronic phase of chronic myeloid leukemia 
had been diagnosed, he was treated with imatinib 
• In March 2010, imatinib treatment was completed and the BCR/ABL fusion 
gene had become undetectable by real time quantitative PCR 
• Subsequently, leukocyte counts and the hematocrit gradually rose 
• In August 2012, a bone marrow aspirate showed hypercellular marrow 
with marked erythroid hyperplasia and the presence of the JAK2 gene 
V617F mutation  
http://dgcases.docguide.com/polycythemia-vera-developed-after-major-molecular-response-imatinib-mesylate-treatment-patient  
 
 Polycythemia vera developed after a major molecular response 
to imatinib mesylate treatment in a patient with CML 
Chronic myelogenous leukemia (CML): 
clinical case 3   
• Patient was diagnosed with polycythemia vera 
• Phlebotomy and chemotherapy were started in addition to imatinib 
administration 
• Shortly thereafter complete blood counts returned to normal levels 
http://dgcases.docguide.com/polycythemia-vera-developed-after-major-molecular-response-imatinib-mesylate-treatment-patient  
 
 Polycythemia vera developed after a major molecular response 
to imatinib mesylate treatment in a patient with CML 
Chronic lymphocytic leukemia (CLL): 
definition 
Chronic lymphocytic  leukemia (CLL) is a 
monoclonal disorder characterized by a 
progressive accumulation of small, mature-
appearing functionally incompetent 
lymphocytes in blood, bone marrow, and organs 
http://oncolex.org/Leukemia/Background/Staging  
Chronic lymphocytic leukemia (CLL): 
epidemiology 
Incidence of CLL by age 
https://www.onkopedia-guidelines.info/en/onkopedia/archive/guidelines/chronic-lymphocytic-leukemia/version-30052015T091206/@@view/html/index.html  
• CLL is characterized by the clonal expansion of CD5+CD23+ B cells in 
blood, marrow, and second lymphoid tissues 
• There is no single specific cytogenetic abnormality in CLL   
•  The most common cytogenetic alteration is deletion 13q14 (51%), 
followed by deletion 11q22-q23 (17%-20%), trisomy 12(15%), and 
deletion 17p13 
• Complex abnormalities may be present: patients with trisomy 12 
may have simultaneous 13q14 deletions    
• A number of cytogenetic abnormalities (trisomy 12 and the 
presence of 14q, 11q, and 17p chromosome abnormalities) have 
been related to poor outcome 
• The biology of CLL is entwined with its microenvironment, in which 
accessory cells can promote leukemia cell growth and/or survival 
Chronic lymphocytic leukemia (CLL): 
mechanisms 1 
http://theoncologist.alphamedpress.org/content/4/5/352.full  
Chronic lymphocytic leukemia (CLL): 
mechanisms 2 
• Trisomy 12 is associated with atypical lymphocyte morphology 
and immunophenotype (CD5–, FMC7+, strong immunoglobulin 
expression) and disease progression 
• Patients with 11q deletions tend to be younger, with an 
advanced clinical stage at presentation associated with 
extensive peripheral, abdominal, and mediastinal 
lymphadenopathy, and a treatment-free interval of nine 
months in contrast to 43 months for those without the 
deletion 
• Chromosome 17 abnormalities have been associated with p53 
mutation, fludarabine-resistance therapy, and therapy failure 
in patients with Richter's syndrome, atypical CLL morphology, 
and prolymphocytic leukemia (PLL)  
 http://theoncologist.alphamedpress.org/content/4/5/352.full  
Chronic lymphocytic leukemia (CLL): 
mechanisms 3 
• The presence of IgV gene mutations is associated with the 
lack of CD38 expression in a group of patients with good 
clinical outcome and better survival  
• CLL is characterized by accumulation of small, mature-
appearing lymphocytes in blood, bone marrow, and organs 
• Recently, much attention is focused on the CLL B cell receptor 
(BCR) and on chemokine receptors that enable CLL cells to 
home to lymphoid tissues and to establish the leukemia 
microenvironment 
• Agents that can interfere with BCR signaling or chemokine–
receptor signaling, or that target surface antigens selectively 
expressed on CLL cells, promise to have significant therapeutic 
benefit in patients with this disease  
 http://theoncologist.alphamedpress.org/content/4/5/352.full  
Chronic lymphocytic leukemia (CLL): 
mechanisms 4 
CLL tumor niches 
http://www.cll-workshop.onkologie-salzburg.com/cll.html  
Chronic lymphocytic leukemia (CLL): 
mechanisms 5 
Transformation of Chronic Lymphocytic Leukemia   
http://annals.org/article.aspx?articleid=706496  
Chronic lymphocytic leukemia (CLL): 
classification 1 
http://oncolex.org/Leukemia/Background/Staging  
 
 
Stage division of CLL according to Binet 
Criteria Stage 
  A B C 
Number of 
involved lymph 
node regions 
0–2 3–5 0–5 
Hemoglobin (g/dl) >10 >10 <10 
Thrombocytes 
(109/l) 
>100 >100 <100 
Survival (years) >10 5 2.6 
Chronic lymphocytic leukemia (CLL): 
classification 2 
Stage division of CLL according to Rai  
0   - characterized by absolute lymphocytosis (>15,000/mm3) without 
adenopathy, hepatosplenomegaly, anemia, or thrombocytopenia 
I  - characterized by absolute lymphocytosis with lymphadenopathy without 
hepatosplenomegaly, anemia, or thrombocytopenia 
II  - characterized by absolute lymphocytosis with either hepatomegaly or 
splenomegaly with or without lymphadenopathy 
III - characterized by absolute lymphocytosis and anemia (hemoglobin <11 
g/dL) with or without lymphadenopathy, hepatomegaly, or splenomegaly 
IV - characterized by absolute lymphocytosis and thrombocytopenia 
(<100,000/mm3) with or without lymphadenopathy, hepatomegaly, 
splenomegaly, or anemia 
https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia#Diagnosis  
 
 
Chronic lymphocytic leukemia (CLL): 
clinical presentation 1 
• About 40%-60% of patients with CLL are diagnosed in the absence of 
disease-related symptoms, even with very high numbers of circulating 
lymphocytes >100 × 109/l 
• Frequently, the presence of lymphadenopathy or an abnormal CBC 
performed during a routine medical examination is the only reason to 
consider the diagnosis  
• The remaining patients may present with weakness, fatigue, night sweats, 
fever, and may be with or without infections or autoimmune diseases 
• Physical examination generally reveals nontender, painless, and mobile 
lymphadenopathy, splenomegaly, or hepatomegaly 
http://theoncologist.alphamedpress.org/content/4/5/352.full  
 
 
Chronic lymphocytic leukemia (CLL): 
clinical presentation 2 
• Metabolic abnormalities (e.g., hyperuricemia) or mechanical disorders 
(e.g., airway obstruction) related to the tumor burden, may also be 
present 
• Any part of the body, including skin and meninges may be infiltrated by 
CLL cells; however, such findings are uncommon 
• Manifestations of bone marrow (BM) involvement, particularly 
significant anemia (hemoglobin <11g/dl) or thrombocytopenia 
(platelets count <100 × 109/l), are noted at presentation in 15% of CLL 
patients 
• A positive direct antiglobulin test (DAT) is present in about 20% of 
patients at diagnosis but is not commonly associated with hemolytic 
anemia   
http://theoncologist.alphamedpress.org/content/4/5/352.full  
 
 
Chronic lymphocytic leukemia (CLL): 
clinical presentation 3 
Massive adenopathy involving the neck, from the level of 
the mastoid to the supraclavicular fossa, and large nodal 
masses in both axillae 
http://escholarship.org/uc/item/8ts5q1b3  http://www.nejm.org/doi/full/10.1056/NEJMicm071065  
 
 
Zosteriform B-Cell CLL 
infiltration 
Chronic lymphocytic leukemia (CLL): 
diagnosis 1 
The National Cancer Institute-Sponsored Working Group diagnosis and 
response criteria for CLL 
• The peripheral blood should exhibit an increase in the number of small 
mature-appearing lymphocytes to >5,000/μl 
• The bone marrow (BM) aspirate smear must show >30% of all nucleated 
cells to be lymphoid 
• Although a BM examination is rarely required to make the diagnosis of CLL 
in general practice, it may be valuable prior to the start of treatment in 
order to define prognostic factors 
• Subsequently, a BM examination is indicated primarily to evaluate response 
to treatment or to assess normal elements if there is an unexplained 
anemia or thrombocytopenia 
http://theoncologist.alphamedpress.org/content/4/5/352.full  
 
 
Chronic lymphocytic leukemia (CLL): 
diagnosis 2 
B-cell chronic lymphocytic leukemia: 
compare the cell size of CLL cells with a 
single large granular lymphocyte (curved 
arrow)  
http://www.pathpedia.com/education/eatlas/histopathology/blood_cells/chronic_lymphocytic_leukemia_(cll)_b-cell.aspx  http://www.forpath.org/workshops/minutes/0011/case03.asp  
 
 
The BM biopsy shows a global cellularity 
within normal range, although 
somewhat heterogeneous: three cell 
lines present with maturation 
Chronic lymphocytic leukemia (CLL): 
diagnosis  
Clonal B cells (orange) in bone marrow with an immunophenotype characteristic 
of CLL: CD5+, CD10-, CD20dim+, CD23+, FMC7-, and dim+ surface λ light chain. 
The cells also are CD19+ and CD38-. Clonal B cells represent 2.2% of events; 
benign polytypic B cells (blue), 4.9%; and normal precursor B cells (hematogones; 
magenta), 1.0%. 
http://www.medscape.com/viewarticle/490055_3  
 
 
Chronic lymphocytic leukemia (CLL): 
treatment 1 
• CLL treatment focuses on controlling the disease and its symptoms rather 
than on an outright cure 
• CLL is treated by chemotherapy, radiation therapy, biological therapy, 
or bone marrow transplantation 
• Symptoms are sometimes treated surgically (splenectomy removal of 
enlarged spleen) or by radiation therapy ("de-bulking" swollen lymph 
nodes) 
• Initial CLL treatments vary depending on the exact diagnosis and the 
progression of the disease, and even with the preference and experience 
of the health care practitioner 
• An initial treatment regimen that contains fludarabine, cyclophosphamide, 
and rituximab (known as FCR) has demonstrated higher overall response 
rates and complete response rates 
https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia#Diagnosis  
 
 
Chronic lymphocytic leukemia (CLL): 
treatment 2 
• Physicians use a “watchful waiting” mode  until the disease progressed, but 
the novel prognostic markers indicate that 50% of patients have a poor 
outcome 
• An early start of therapy may be justified in patients with a poor prognosis 
• Since CLL cells must interact with the stroma in bone marrow or lymphoid 
tissues to survive, these interactions need to be explored as targets of 
innovative therapies, and specific inhibition of the B-cell receptor signaling 
pathway, as  targeting the actively proliferating cells that maintain the CLL 
clone by a cell-cycle–active agent may be an option 
• Since as 20% of patients with the worst prognostic markers have stereotypic 
antigen receptors, they may be valuable points of attack  
http://www.nejm.org/doi/full/10.1056/NEJMra041720  
Chronic lymphocytic leukemia (CLL): 
prognosis 
• Prognosis depends on the subtype 
• Some subtypes have a median survival of 6–8 years, while others have a 
median survival of 22 years (which is a normal lifespan for older patients) 
• Telomere length has been suggested to be a valuable prognostic indicator 
of survival 
https://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia#Diagnosis  
 
 
Chronic lymphocytic leukemia (CML): 
clinical case 1   
• Granulomatous cutaneous reactions are well described in association with 
T-cell non-Hodgkin lymphoma and Hodgkin lymphoma, but are rarely seen 
in association with B-cell non-Hodgkin lymphoma or leukemia 
• Doctors report a case of a 65-year-old woman with B-cell chronic 
lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who 
presented with multiple, tender, firm pink papules on the face, upper trunk 
and upper extremities 6 years after diagnosis of CLL 
• Biopsy revealed both palisading granulomatous dermatitis consistent with 
actinic granuloma and a dense perivascular lymphocytic infiltrate 
consistent with the patient's known history of leukemia 
• This is an unusual manifestation of cutaneous B-cell CLL that is rarely seen 
http://dgcases.docguide.com/actinic-granuloma-occurring-unusual-association-cutaneous-b-cell-chronic-lymphocytic-leukemia  
 
 Actinic granuloma occurring in an unusual association with 
cutaneous B-cell CLL 
Chronic lymphocytic leukemia (CML): 
clinical case 2  
• Chronic lymphocytic leukemia/lymphoma (CLL) is an extremely rare 
disease during childhood 
• Doctors report a 16-year-old female who presented with 
lymphadenopathies and she was diagnosed as T cell lymphoblastic 
lymphoma 
• Her chemotherapy response was minimal and clinical findings were 
unusual 
• Her biopsy specimen was re-examined and diagnosis was changed to CLL 
• Chemotherapy protocol including fludarabine, cyclophosphamide, 
rituximab was administrated and good response was observed  
http://dgcases.docguide.com/actinic-granuloma-occurring-unusual-association-cutaneous-b-cell-chronic-lymphocytic-leukemia  
 
 CLL in a child 
Prophylaxis 
Patients with leukemia in periods of severe 
granulocytopenia and thrombocytopenia related 
to the specific antileukemic therapies 
administered demand secondary prophylaxis 
with antifungals and antibiotics  
http://www.uptodate.com/contents/prevention-of-infections-in-patients-with-chronic-lymphocytic-leukemia  
Abbreviations  
• ALL - acute lymphoblastic leukemia  
• AML - acute myelogenous leukemia  
• BM – bone marrow  
• CALLA - common acute lymphoblastic leukemia antigen  
• CARs - Chimeric antigen receptors  
• CLL - chronic lymphocytic leukemia  
• CML - chronic myelogenous leukemia  
• CNS - central nervous system 
• DCL - donor cell leukemia 
• FAB - French-American-British classification 
• FFP - fresh frozen plasma 
• ROM - range of motion 
• SCT - stem cell transplant 
• TdT - terminal deoxynucleotidyl transferase  
• TENS - transcutaneous electrical nerve stimulation 
• WHO - World Health Organization  
• PCR  - polymeric chain reaction 
• FDA - U.S. Food and Drug Administration  
Diagnostic guidelines 
Europe 
• Peripheral T-Cell Lymphomas: ESMO Clinical Practice Guidelines  
• Diffuse Large B-Cell Lymphoma: ESMO Clinical Practice Guidelines 
• Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines 
• Hairy Cell Leukaemia: ESMO Clinical Practice Guidelines 
• Philadelphia Chromosome-Negative Chronic Myeloproliferative 
Neoplasms: ESMO Clinical Practice Guidelines 
• Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines 
• New aspects of the updated guidelines for the diagnosis and 
treatment of chronic lymphocytic leukemia 
 
North America 
• Leukemia: An Overview for Primary Care 
 
